Allt inom Yearend

“The fourth quarter of 2020 was one of the most eventful in Nanexa’s history. We received a GMP certificate for drug manufacturing and a clinical trial permit for our NEX-18 project. We signed a collaboration agreement with Applied Materials and an investment agreement with Applied Ventures and, after careful evaluation, we decided shortly after the end of the quarter to choose lenalidomide for our NEX-20 project.” David Westberg, CEO Nanexa